The Risks and Benefits of Current Treatment Options for Prostate Cancer and Future Possibilities in Advanced Imaging and Targeted Therapy – A Review

Emma Huebner and Al Barqawi
Division of Urology, Department of Surgery, University of Colorado Denver School of Medicine, Aurora, Colorado, USA

Background

242,000 cases of prostate cancer are diagnosed annually, rendering it the most common noncutaneous cancer and the second highest cause of cancer death among men [1]. However, the majority of prostate cancers are indolent in progression, and the risk of cancer-specific mortality is just 3.7% [1,2]. The incidence and mortality of prostate cancer are largely inconsistent, and the advent of PSA screening has contributed to overdiagnosis and overtreatment [3,4]. Overdiagnosis can be defined as the detection of prostate cancer during screening that would not have been clinically diagnosed throughout a man's lifetime in the absence of screening [5]. PSA testing can identify disease 6 to 13 years before it presents clinically, and therefore overdiagnosis is a substantial consequence, especially because prostate cancer is generally diagnosed in older men [2,5,6]. 10-56% of tumors never lead to clinical symptoms, and detection of prostate cancer during autopsy studies has been reported as high as 60-70% [7,8].

Based on Microsimulation Screening Analysis, 98 men would need to be screened and 5 cancers detected in order to prevent one prostate cancer-specific death [5]. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial found no significant difference in mortality between individuals undergoing organized annual screening and those undergoing opportunistic screening at 13 years follow-up, despite annual screening resulting in a 12% relative increase in prostate cancer diagnoses [9]. This increase is representative of the problem created by overdiagnosis in the era of PSA screening; more cancers are detected, but no more lives are saved.

The levels of overdiagnosis and overtreatment are widely variable, with overdiagnosis estimates ranging from 1.7% to 67% of cases detected by PSA screening [10]. Nonetheless, the unspecific nature of PSA screening inhibits physicians from determining which patients will progress to fatal disease [2,7,11]. The growing prevalence of unilateral pT2a and pT2b prostate cancers is partially attributable to the role of PSA screening in the trend toward earlier diagnosis and intervention, which has resulted in profound stage migration [12]. In fact, evidence shows that the introduction of PSA testing has led to the systematic reclassification of Gleason scoring, resulting in a superficial improvement in clinical outcomes [13,14]. As Gleason scores are the most powerful indication of prognosis and treatment recommendation, their reclassification has established a lower PSA threshold for biopsy and has promoted the performance of repeat biopsies for negative findings, resulting in overdiagnosis and overtreatment [15,16]. Annual PSA screening for prostate cancer was given a level D recommendation by the US Preventative Health Task Force in 2011, resulting in a 28% decline in incident diagnoses of low, intermediate, and high-risk prostate cancers in the following year, most significantly in men over the age of 50 [17,18]. While the recommendation may have reduced the rate of overdiagnosis, especially in older cohorts with higher comorbidities, it may have also caused more aggressive cancers to be overlooked. Both overtreatment of low-risk disease (PSA≤10 ng/mL, Gleason score ≤6, T1a-c or T2a tumor) and undertreatment of high-risk disease (PSA>20 ng/mL or Gleason score 8-10 or T2c tumor) are evident in current treatment patterns, warranting the development of new molecular and genetic indicators and imaging techniques for more precise detection of disease progression [8,15,19]. The purpose of this article is to provide an extensive review of current diagnostic tools and treatment options for prostate cancer and to outline how the standard of care is changing to meet new developments in clinical and translational research.

Review of the Literature

PSA screening

Prostate cancer is not the only cause of elevated PSA serum levels; high PSA can also be associated with the three most common prostatic diseases – prostatitis, BPH, and prostate cancer – as well as physical activity, infection, and medication, the latter of which can also suppress PSA levels [20]. Despite these complications, PSA concentration has been strongly correlated with prostate cancer metastasis 25-30 years after screening, suggesting that early testing is useful for identifying patients with the highest risk [21,22]. Vickers et al. [22] reports a 15-year risk of prostate cancer metastasis to be 0.09% from ages 45-49 and 0.28% from ages 51-55, supporting the conclusion that just three lifetime PSA tests would be sufficient for detecting clinically significant cancer in at least 50% of the male population. The cost-effectiveness of the screening diminishes in older patients due to loss of quality of life from overdiagnosis; data suggest that over the age of 60, only patients with PSA levels >2 ng/mL would benefit from continued screening [23,24]. In a sampling of men with nonmetastatic prostate cancer from the Prostate Cancer Outcomes Study, Daskivich et al. [25] documented an other-cause mortality rate of greater than 50% for those with multiple comorbidities over the age of 60. At 14 years, prostate cancer mortality was 5% for men with low-risk disease and 23% for men with high-risk disease. These data suggest that older men with localized prostate cancer diagnoses should consider conservative management to maintain maximum quality of life, given the likelihood of non-cancer related death.

PSA doubling time has been used as an indication of biochemical failure in patients initially under active surveillance. A 99.3% prostate cancer specific survival rate at 8 years post-diagnosis was reported in patients initially under active surveillance but who were offered...
Curative treatment

The effectiveness of curative treatments such as radical prostatectomy, external beam radiation, and brachytherapy is not entirely clear. The risk of recurrence after radical prostatectomy in particular is highly variable. Despite intervention by radical prostatectomy, a PSA level increase of >2.0 ng/mL in the year before prostate cancer diagnosis was reported to be indicative of prostate cancer-specific mortality [26,27]. Radical prostatectomy has been shown to decrease all-cause mortality if PSA>10 ng/mL and has yielded a 6% reduction in bone metastases 8 years post-treatment, but no significant benefit is evident if PSA<10 ng/mL; in fact, up to a 4% greater mortality was observed in radical prostatectomy patients with PSA<10 ng/mL when compared to those under observational management [7,16]. In patients with PSA levels of at least 19.7, a retrospective study of prostate cancer patients treated by external-beam radiation therapy reported less than 50% biochemical cancer-free survival rate [28]. Therefore, in both low-risk and high-risk cancers, radical intervention has not been shown to consistently produce successful outcomes.

A study of pre-PSA era prostate cancer treatment in patients under the age of 65 did show a reduction in prostate cancer-specific mortality rate 15 years post radical prostatectomy (14.6%) in contrast to a 20.7% rate in patients managed under a watchful waiting program [29]. However, because these cancers were not detected by PSA screening, it is likely that there was a greater extent of more clinically advanced cancers in the cohort that was studied. The insignificance of mortality reductions by radical intervention observed in the Prostate Cancer Intervention versus Observation Trial (PIVOT) study reflect in part the more favorable prognosis of patients with tumors detected by PSA screening. The resulting lead time and increased rates of overdiagnosis have led to a greater number of low risk, clinically insignificant tumors that naturally yield better outcomes [16,30].

While prostate cancer-specific mortality is not necessarily hindered by radical intervention, data suggest that these treatments do impair quality of life. Multiple studies, including data from the U.S. CaPSURE registry, have shown that radical prostatectomy patients are more likely to suffer from urinary incontinence than radiotherapy patients and are also more likely to have higher rates of impotency, although both groups report high erectile dysfunction rates (62-94%) [31-34]. Complications related to bowel function affect individuals treated by both radical prostatectomy and radiotherapy, but radiotherapy patients have been indicated to experience more significant declines [32-34].

While these deteriorations in quality of life are significant, it is important to compare them with age-adjusted normative data. In a study of older men (median age 72.5) without prostate cancer, approximately a third reported urinary leakage, a third rectal dysfunction, and almost two-thirds erectile dysfunction [35]. These findings emphasize the importance of comparing functional outcomes of prostate cancer patients with controls of the same age. However, multiple studies have revealed that while no significant difference in overall health-related quality of life exists between prostate cancer patients who have undergone radical prostatectomy and age-adjusted controls, the sexual, bowel, and urinary functions of radical prostatectomy patients have declined more substantially than that of controls [36-39]. Multi-model treatment and particularly the use of androgen deprivation therapy have been associated with the highest risk of adverse effects and the greatest impairment to physical function [34,39,40].

Some functional stabilization is evident in the recovery process, with those experiencing early functional impairment from radical prostatectomy or brachytherapy reporting a return to baseline, with the exception of sexual function, within 2 years of treatment [41]. Other findings, however, have indicated consistent functional declines in urinary and sexual function 5 years post-treatment, despite some evidence of stabilization between 2 and 5 years [31]. These conclusions designate the importance of long-term follow-up data in fully assessing functional outcomes of aggressive and conservative treatment modalities for prostate cancer.

Active surveillance

Data from the PIVOT study provide long-term results and strong support for the effectiveness of active surveillance, in which curative treatment is delayed until cancer progression is detected. PIVOT results did not show a significant difference in the number of prostate-cancer specific deaths between radical prostatectomy patients and patients under observation [16]. Multiple studies have reported 94-99% 10-year cancer-specific survival rates in men under active surveillance for low-risk and intermediate-risk prostate cancer, compared to the 90% rate reported for a similar cohort treated by radical prostatectomy [42-45]. There is no difference in overall survival rates between patients who remain on surveillance and those who seek deferred treatment [46]. Annual mortality rates of low-grade prostate cancer patients under active surveillance have been reported to remain stable at 15 years post-diagnosis, and similar or better health-related quality of life outcomes have been documented for those in watchful waiting programs when compared to controls [13,47]. The most common cause of death among active surveillance patients is cardiovascular disease, and the relative risk of non-prostate cancer related mortality has been calculated to be 10 times more likely than death due to prostate cancer [46]. The low risk of prostate-cancer specific mortality suggests that radical intervention in the case of low-grade prostate cancers may not be warranted, despite the prevalence of aggressive therapies such as radical prostatectomy in the U.S. today [19].

Regardless of the compelling evidence for the utilization of conservative management, data reviewed from the U.S. CaPSURE registry revealed that just 6.8% of men with biopsy-proven prostate cancer choose to follow an active surveillance treatment plan, in comparison to 49.9% who elect to undergo radical prostatectomy, 11.6% external-beam radiation therapy, 14.4% primary androgen deprivation monotherapy, and 13.3% brachytherapy. Risk assessment and the physician’s recommendation to the patient have been identified as critical reasons behind treatment selection [48]. Of those who choose active surveillance, as many as 50% switch to deferred treatment after 3-5 years, and only 40% undergo a repeat biopsy at 12 months. This lack of adherence demonstrates the need for the development of alternative biomarkers to decrease morbidity. Reduction in the variability of active surveillance enrollment criteria and continual encouragement of patients to follow their observational management programs is also needed in order to increase utilization of active surveillance programs [51,49]. Active surveillance is an
underused treatment strategy in part because healthcare providers do not consistently discuss it as a treatment option, or clinicians present it in a negative way. Discouragement from electing active surveillance has compelled patients and their care providers to pursue more aggressive treatment modalities [2,48,50]. A review of decision aids for the treatment of prostate cancer, 8 of which were developed in the U.S., found none to meet International Patient Decision Aid Standards. Some of the aids failed to address active surveillance as a treatment option or the risk of overtreatment when selecting more radical intervention [51]. This problem is not necessarily prevalent in healthcare systems outside of the United States. In comparison to U.S. data, a Swedish study reported that 59% of very low-risk and 41% of low-risk prostate cancer patients opted for active surveillance from 1998-2011, suggesting that overtreatment is beginning to decline internationally [48].

The lack of election and adherence to active surveillance in the U.S. is indicative of the observed patterns in overtreatment of low-risk disease, but undertreatment of high-risk disease has also been identified [7,19,52]. The 10-year cancer specific survival rate for prostate cancer patients treated by initial observational management for poorly differentiated disease (Gleason score 8-10) was reported to be 58-74%, suggesting that this group would have benefited appreciably from more aggressive treatment modalities [42]. The absence of biomarkers for disease aggressiveness prevents the development of active surveillance as a treatment option for low-risk prostate cancer. The ambiguity that exists in distinguishing between clinically significant and insignificant cancers has compelled physicians and their patients to resort to more radical treatment options in order to prevent undertreatment.50 The patterns of overtreatment and undertreatment have established the need for the development of more moderate treatment modalities that lie between observational management and radical intervention in the continuum of prostate cancer management.

**Future Treatment Modalities**

**Targeted focal therapy**

The development of targeted focal therapy (TFT) shows promise in bridging the gap between active surveillance and more aggressive therapies. With respect to prostate cancer, TFT has been defined as the use of a minimally invasive technique to ablate all clinically significant cancer foci in the prostate [7,53,54]. The increasing diagnoses of unilateral prostate cancer, in part due to PSA screening, has allowed for augmented use of novel focal ablative therapies. The number of focal treatments per year has increased from 46 in 1999 to 567 in 2007 [12,55]. Ablative options for focal treatment include cryotherapy, brachytherapy, radiotherapy, thermotherapy, and high intensity focused ultrasound (HIFU) [2]. HIFU has yielded a 92% negative biopsy rate post-treatment in low-risk prostate cancer patients [56].

Advancement in imaging technology has allowed for the development of focal cryotherapies that have produced higher erectile function and equivalent biochemical recurrence survival rates at 60 months when compared to whole-gland cryoablation [53,56,57]. Partial gland cryoablation has yielded 75.7% to 84% biochemical recurrence-free rates, 98.4% to 100% urinary continence, 86% sexual potency, and 75% negative biopsies [55,58,59]. While cryotherapy is a more expensive surgical procedure than radical prostatectomy, the overall direct costs of cryotherapy ($9,195) are less than radical prostatectomy ($10,704), due to shorter hospital stays, lack of pathologic costs, and the absence of the need for blood transfusions [60].

No universally accepted biochemical definition has been developed for follow-up protocol after cryotherapy, but the achievement of PSA nadir <0.1 ng/mL has yielded the lowest incidence of biochemical failure within 18 months of cryosurgery [61]. CaPSURE data indicate that just 4.0% of prostate cancer patients elect for cryoablation; long-term follow-up data from additional studies of TFT are needed in order to determine proper patient selection and increase the utilization of focal ablation, but TFT already holds promise as a pragmatic approach for treating low-risk prostate cancer [19,54].

**Diagnostic imaging**

A crucial influence in the advancement of targeted focal therapy is the improvement of prostate imaging. Transrectal ultrasound (TRUS), the most commonly utilized imaging modality in prostate biopsies, has a 14.3% false-negative rate and tends to undersample the anterior zone, apex, and anterolateral horn of the prostate [53,62-64]. Gleason scores obtained from TRUS biopsy agree with radical prostatectomy specimen Gleason scores only 28.7% of the time [65]. Recent studies have advocated for implementation of endorectal magnetic resonance imaging (MRI) in the assessment of patient eligibility for active surveillance. Clear tumor visualization on prostate MRI is predictive of Gleason score upgrades on confirmatory biopsies [66].

The introduction of 3-dimensional mapping biopsy (3DMB) has also displayed a substantial advancement in the evaluation of prostate cancer. A 3DMB study revealed that 61.1% of all patients and 50% of low-risk patients with unilateral prostate cancer diagnosed by TRUS biopsy actually had bilateral disease [67]. The utilization of 3DMB in the treatment of patients with TRUS biopsy-confirmed early-stage, organ confined prostate cancer yielded a Gleason score upgrade and up-stage in 27.2% and 45.6% of all cases, respectively [62]. 3DMB has the potential to omit a significant number of patients from active surveillance programs and in doing so avoid cases of undertreatment. This improvement in imaging will provide physicians with greater confidence and assurance when assessing the most pragmatic course of treatment for their patients.

The development of 3DMB and focal ablative therapies are helping to elucidate the distinction between mortal and non-mortal prostate cancers. These improvements have lead to the establishment of risk-stratified protocols that will avoid both overtreatment and undertreatment tendencies. The advancement of imaging technology is a crucial factor in eliminating the uncertainty that surrounds the treatment selection process and in increasing the utilization of active surveillance and less aggressive treatment modalities for the maximization of patient quality of life. Improved imaging and targeted biopsy techniques are also essential for the success of molecular profiling of prostate cancer. As cancer treatment progresses towards more personalized therapies, molecular classification of malignant tumors will ensure detection of more aggressive lesions that may be independent of initially detected low-grade cancer [68].

**Genomic testing**

Genomic testing is a prospective technique for clarifying the metastatic and local invasive potentials of individual tumors, while epigenetic alterations and selective modulation of microRNAs also hold therapeutic potential for all urologic cancers [26,69,70]. Data suggest that the addition of genomic information to traditional
diagnostic variables does yield some improvement in prognostic accuracy [26]. Current approaches include the identification of molecular alterations of prostate cancer in order to develop clinically available expression profiling data for future patients. Tomlins et al. [71] classified patient expression profiles into subtypes in order to characterize the clinical and molecular characteristics of those subtypes. Researchers found through multivariate analysis that m-ERG + tumors were significantly associated with lower Gleason score, lower PSA, and European American ethnicity. m-ETS+ prostate cancer was significantly associated with increased seminal vesicle invasion, and m-SPINK1+ tumors, molecularly similar to triple negative prostate cancer, were overexpressed in African Americans.

A 17-gene RT-PCR diagnostic assay that yields a Genomic Prostate Score (GPS) has been clinically validated to predict biochemical recurrence, adverse pathology and metastasis in men with low and intermediate risk prostate cancers [72]. The GPS assay and other commercially available genomic tests provide additional support for treatment recommendation in the management of prostate cancer.

**Conclusion**

$11.85 billion was spent on prostate cancer care in the U.S. in 2010 [73]. The pervasiveness of prostate cancer and the harmful consequences of the current standard of care have led to unnecessary deterioration of quality of life and rampant costs of treatment. The uncertainty in distinguishing between aggressive and indolent lesions has warranted the improvement of imaging techniques, genetic biomarkers, and targeted therapies in order to more appropriately treat individual cancers. More long-term data are needed in order to determine the effectiveness of targeted therapies, and a larger volume of patient expression profiles must be classified as the transition away from generalized screening towards more precise genomic testing is completed.

**Acknowledgment**

This work was drafted as part of the University of Colorado Cancer Research Summer Fellowship, supported by the University of Colorado Cancer Center and the Cancer League of Colorado. I would like to thank my preceptor Dr. Al Barqawi for providing insight and guidance in writing this paper.

**References**

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Barqawi AB, Krughoff KJ, Eid K (2012) Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Adv Urol 2012: 862639.
3. Etzioni R, Penson R, Legler JM, di Tommaso D, Boer R, et al. (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990.
4. Van der Kwast TH, Roobol MJ (2013) Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 10: 473-482.
5. Heijnsdijk EA, Wever EM, Auvinen A, Hugoson J, Ciatto S, et al. (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367: 595-605.
6. Draisma G, Boer R, Otto SJ, van der Cruyssen IW, Dammhuis RA, et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878.
7. Smith DW, Stiromenova D, Eid K, Barqawi A (2012) The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges. Prostate Cancer 2012: 587139.
8. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, et al. (2007) Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. J Urol 177: 2106-2131.
9. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132.
10. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, et al. (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65: 1046-1055.
11. Klotz L (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24: 46-50.
12. Polascik TJ, Maves JM, Sun L, Maddern JF, Moul JW, et al. (2008) Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68: 1380-1386.
13. Albertsen PC, Hanley JA, Barrows GH, Penson DE, Kowalczyk PD, et al. (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97: 1248-1253.
14. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNell SA (2005) Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. Eur Urol 47: 196-201.
15. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, et al. (2012) National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer. Ann Intern Med 156: 591-595.
16. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, et al. (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213.
17. Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, et al. (2015) The effect of the United States Preventative Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US. J Urol 194: 1587-1593.
18. Brajkov MW, Huo D, Eggener SE (2015) National Prostate Cancer Screening Rates After the 2012 US Preventative Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol.
19. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123.
20. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, et al. (2001) Prostate-specific antigen best practice policy – part 1: early detection and diagnosis of prostate cancer. Urology 57: 217-224.
21. Ulmert D, Cronin AM, Bjork T, O'Brien ME, Scardino PT, et al. (2008) Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6: 6.
22. Vickers AJ, Ulmert D, Sjoberg DD, Bennett CJ, Bjork T, et al. (2013) Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastatic case-control study. BMJ 346: f2023.
23. Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, et al. (2014) Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 107: 366.
24. Carlsson S, Asell M, Sjoberg D, Ulmert D, Hugoson J, et al. (2014) Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 348: g2296.
25. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, et al. (2015) Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology 85: 92-100.
26. Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja HS, et al. (2015) Genomic Predictors of Outcome in Prostate Cancer. Eur Urol 68: 1033-1044.

27. D'Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135.

28. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, et al. (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281: 1598-1604.

29. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, et al. (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364: 1708-1717.

30. Xia J, Gulati R, Au M, Gore JL, Lin DW, et al. (2013) Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Institute 105: 346-350.

31. Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, et al. (2013) Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int 111: 213-220.

32. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, et al. (2000) Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92: 1582-1592.

33. Madalinska JB, Eeink-Boit ML, de Koning HJ, Kirkels WJ, van der Maas PJ, et al. (2001) Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19: 1619-1628.

34. Punnunen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR3 (2015) Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol 68: 600-608.

35. Litwin MS (1999) Health related quality of life in older men without prostate cancer. J Urol 161: 1180-1184.

36. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, et al. (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23: 2772-2780.

37. Hjalm-Eriksson M, Lennernas B, Ullen A, Johansson H, Hugosson J, et al. (2015) Long-term health-related quality of life after curative treatment for prostate cancer: a regional cross-sectional comparison of two standard treatment modalities. Int J Oncol, 46: 381-386.

38. Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, et al. (2004) Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 101: 2011-2019.

39. Carlsson S, Drevin L, Loob S, Widmark A5, et al. (2015) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int .

40. Sanda MG, Dunn JL, Michalski J, Sandler HM, Northouse L, et al. (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358: 1250-1261.

41. Downs TM, Sadesky N, Pasta DJ, Grossfeld GD, Kane CJ, et al. (2011) Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer – data from CaPSURE. J Urol 170: 1822-1827.

42. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, et al. (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302: 1202-1209.

43. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasanainen H, et al. (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110: 1672-1677.

44. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, et al. (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102: 950-958.

45. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277: 467-471.

46. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, et al. (2010) Clinical results of long-term follow-up of large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 126-131.

47. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, et al. (2008) Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol 179: S14-S18.

48. Loeb S, Berglund A, Stattin P (2013) Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 190: 1742-1749.

49. Philippou Y, Raja H, Gnanapragasam VJ (2015) Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists, and urology nurse specialists across three cancer networks in the United Kingdom. BMC Urol 15: 52.

50. Pensio DF (2009) Active surveillance: not your father's watchful waiting. Urology 73: 141-145.

51. Adul P, Wray R, Spradling K, Darwish O, Weaver N, et al. (2015) Systematic Review of Decision Aids for Newly Diagnosed Prostate Cancer Patients Making Treatment Decisions. J Urol 194: 1247-1252.

52. Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990-2007. World J Urol 26: 211-218.

53. Crawford ED, Barqawi A (2007) Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park) 21: 27-32.

54. Barqawi AB, Stonecipher D, Krughoff K, Eid K, O’Donnell C, et al. (2014) Targeted focal therapy for the management of organ confined prostate cancer. J Urol 192: 749-753.

55. Ward J, Jones JS (2012) Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 109: 1648-1654.

56. Nomura T, Mimata H (2012) Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol 2012: 391437.

57. Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ (2015) Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. J Endourol 29: 1193-1198.

58. Ellis DS (2002) Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology 60: 34-39.

59. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, et al. (2012) Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 62: 55-63.

60. Mouraviev V, Nonsik I, Sun L, Robertson CN, Walther P, et al. (2007) Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 69: 311-314.

61. Shinhara K, Rhee B, Presti JC Jr, Carroll PR (1997) Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol 158: 2206-2209.

62. Barqawi AB, Rove KO, Gholidazeh S, O'Donnell CI, Koul H, et al. (2011) The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 186: 80-85.

63. van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, et al. (2015) Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol 33: 907-916.

64. Krughoff K, Eid K, Phillips J, Stonecipher D, Smith D, et al. (2013) The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach. Adv Urol.

65. Cao K, YuCEL S, Turkeri L, Ahdas A (2002) Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens. Int J Urol 9: 257-260.
66. Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, et al. (2012) Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer. J Urol 188: 1732-1738.

67. Onik G, Miesau M, Bostwick DG (2009) Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 27: 4321-4326.

68. Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB3 (2015) Diagnostic challenges of clonal heterogeneity in prostate cancer. J Clin Oncol 33: e38-40.

69. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, et al. (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60: 753-766.

70. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, et al. (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671-681.

71. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousuf K, et al. (2015) Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 68: 555-567.

72. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, et. al. (2015) A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. Eur Urol 68: 123-131.

73. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103: 117-128.